Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): A Multicenter Post-marketing Surveillance Study

ConclusionThe results demonstrated the real-world safety and effectiveness of biosimilar etanercept in patients with RA, PsA, and AS.Trial RegistrationClinicalTrials.gov identifier NCT04582084.

Source: Advances in Therapy - January 11, 2021 Category: Drugs & Pharmacology Source Type: research